Published on 28 May 2024 on Zacks via Yahoo Finance
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Candel Therapeutics CADL, a clinical-stage oncology company, is focused on developing two novel therapeutics, CAN-2409 and CAN-3110, to treat a variety of cancer indications.
The company’s most advanced product candidate, CAN-2409, is an investigational adenovirus immunotherapy candidate that is being developed in separate mid to late-stage studies across three different types of cancer, including, prostate cancer, non-small cell lung cancer (NSCLC) and pancreatic cancer.